Coherus Oncology
CHRS
158 hedge funds and large institutions have $121M invested in Coherus Oncology in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 48 increasing their positions, 36 reducing their positions, and 10 closing their positions.
320% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 10
49% more capital invested
Capital invested by funds: $81.1M → $121M (+$39.7M)
33% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 36
23% more funds holding
Funds holding: 128 → 158 (+30)
0.49% more ownership
Funds ownership: 47.26% → 47.74% (+0.49%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
53% less call options, than puts
Call options by funds: $207K | Put options by funds: $436K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust
Fort Myers,
Florida
|
+$11.4M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$6.09M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4M |
| 4 |
Two Sigma Investments
New York
|
+$3.19M |
| 5 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.49M |
| 2 |
Jane Street
New York
|
-$1,000K |
| 3 |
Millennium Management
New York
|
-$619K |
| 4 |
BlackRock
New York
|
-$351K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$286K |
CHRS Hedge Fund Activity: Q1 2026 in Review
158 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2026, worth a combined $121M — up 49% from $81.1M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CHRS positions and 10 closed out — a net gain of 32 holders — while 48 added to existing stakes and 36 trimmed.
The largest buyer was Timothy G. Youngquist 2020 Irrevocable Trust, adding an estimated $11.4M. The largest seller was Tang Capital Management, cutting an estimated $1.49M.
- 158 institutional investors held Coherus Oncology (CHRS) as of Q1 2026, up from 128 in Q4 2025.
- Funds reported $121M of Coherus Oncology stock for Q1 2026, up 49% quarter-over-quarter.
- 42 funds opened new Coherus Oncology positions in Q1 2026 and 10 closed out, a net change of +32 holders.
- The largest Coherus Oncology buyer in Q1 2026 was Timothy G. Youngquist 2020 Irrevocable Trust, an estimated $11.4M added.
- The largest Coherus Oncology seller in Q1 2026 was Tang Capital Management, an estimated $1.49M sold.
Based on aggregated 13F filings for Q1 2026.